InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes

The largest of three phase 3 studies of the novel investigational SGLT1/SGLT2 inhibitor shows that it improves glycemic control and may reduce body weight and BP but also raises some risks, including DKA.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

AbstractBackgroundObjective binge eating (OBE) is common among individuals with type 1 diabetes (T1D) and may have negative consequences for glycemic control. Recent studies have suggested that diabetes distress (i.e., emotional distress specific to diabetes and living with the burden of management) is a distinct emotional experience among individuals with diabetes. Preliminary studies have found diabetes distress is associated with eating disorder symptoms and poor glycemic control. The aim of the current study was to examine real-time emotional precursors and consequences of OBE in adults with T1D (i.e., general negative...
Source: Journal of Eating Disorders - Category: Eating Disorders & Weight Management Source Type: research
ConclusionsMost patients with DKA presented with mild and moderate DKA and only a minority presented with the severe form of the disease. The etiology of DKA was mainly T1DM and less frequent uncontrolled T2DM, usually due to the co-existence of severe infections, while only in a tiny minority, the causes remained unidentifiable.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
In conclusion, EGPs protected NOD mice against T1D via increasing anti-inflammatory immune responses and decreasing autoreactivity to self-antigens.Graphical abstract
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Publication date: May 2019Source: Journal of Functional Foods, Volume 56Author(s): Suling Sun, Guowei Zhang, Hongyan Mu, Hao Zhang, Yong Q. ChenAbstractCorn peptide promotes glucagon-like peptide-1 release in type 2 diabetic animals, while wheat peptide increases pro-inflammatory cytokine response in type 1 diabetic patients. However, the effect of a mixture of corn and wheat peptide on the initiation and the development of type 1 diabtes remains unclear. Corn peptide reduced the blood glucose in wheat peptide-evoked diabetic NOD mice. A mixture of corn and wheat peptide significantly delayed the initiation and decreased t...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
No abstract available
Source: Exercise and Sport Sciences Reviews - Category: Sports Medicine Tags: Commentaries to Accompany Source Type: research
Recent evidence reveals impairments to skeletal muscle health in adolescent/young adults with type 1 diabetes (T1D). Interestingly, the observed changes in T1D are not unlike aged muscle, particularly, the alterations to mitochondria. Thus, we put forth the novel hypothesis that T1D may be considered a condition of accelerated muscle aging and that, similar to aging, mitochondrial dysfunction is a primary contributor to this complication.
Source: Exercise and Sport Sciences Reviews - Category: Sports Medicine Tags: Articles Source Type: research
Publication date: Available online 15 March 2019Source: Journal of Pharmacological SciencesAuthor(s): Sheng-gao Tang, Xiao-yu Liu, Shan-ping Wang, Hong-hui Wang, Aleksandar Jovanović, Wen TanAbstractDiabetic cardiomyopathy (DCM) is characterized by cardiac hypertrophy, fibrosis, oxidative stress and inflammation. Trimetazidine (TMZ), a potent metabolism modulator, has been shown to be cardioprotective in experimental models of ischaemia-reperfusion and type 2 diabetes-induced cardiomyopathy. The present study examined whether TMZ inhibits cardiomyopathy induced by insulin-dependent type 1 diabetes. Wistar rats were random...
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
In vitro generation of pancreatic β-cells for diabetes treatment. I. β-like cells derived from human pluripotent stem cells. Folia Histochem Cytobiol. 2019 Mar 14;: Authors: Cierpka-Kmiec K, Wronska A, Kmiec Z Abstract Diabetes mellitus is a chronic disease that affects hundreds of millions of people worldwide. Type 1 diabetes (T1D) is characterized by the lack of pancreatic β-cells that had been destroyed as a result of an autoimmune response. Therefore, in patients with T1D, the replacement therapy with functional β-cells derived from extrinsic sources could be a preferable option...
Source: Folia Histochemica et Cytobiologica - Category: Cytology Tags: Folia Histochem Cytobiol Source Type: research
ConclusionThis analysis expands the findings of EU-TREAT by showing differential changes in the clinical endpoints depending on particular need. It introduces the possibility that the differential benefits of degludec could address two of the renowned clinical challenges faced when treating diabetes: improving glycemic control for optimal management of T1D and titrating insulin dose in T2D, both without fear of increased hypoglycemia.Trial RegistrationClinicalTrials.gov, NCT02662114.FundingNovo Nordisk A/S.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
AbstractThe purpose of the current study was to examine executive function (EF) in adolescents with type 1 diabetes using both performance-based and questionnaire measures in relation to diabetes indicators. Adolescents age 13 –17 completed performance-based measures of EF and measures of adherence. Adolescents’ parents reported on adolescents’ EF and adherence. HbA1c and frequency of blood glucose monitoring (glucometer data) were obtained from adolescents’ medical records. None of the performance-based measures of EF were significantly associated with adherence or with HbA1c. Parent-reported probl...
Source: Journal of Behavioral Medicine - Category: Psychiatry Source Type: research
More News: Diabetes | Diabetes Type 1 | Endocrinology | Health | SGLT2 Inhibitors | Study